title: Dehydroepiandrosterone and body fat.
abstract: Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant circulating adrenal steroid in man, yet its physiologic role and that of its parent compound DHEA are unknown. Age-related decreases in DHEA in association with increases in obesity, insulin resistance, and atherosclerosis are well known. Recent investigations in lower mammals (which do not secrete DHEA) have suggested that DHEA (or its metabolites) may function as an antiobesity agent in these models of obesity independent of food intake. Proposed mechanisms for the decrease in fat mass and lower weight gain when DHEA is given orally include increases in futile cycling and peroxisomal beta-oxidation and decreases in de novo lipogenesis. Alterations in the availability of reducing equivalents for lipid synthesis do not appear to explain this decrease. Changes in pancreatic insulin secretion or insulin sensitivity may also be responsible for some of these effects. Studies in humans have failed to demonstrate a beneficial effect of DHEA on body composition or energy expenditure at either pharmacologic or physiologic replacement doses for 1-3 months. Administration of DHEA to men or women has also not been shown to alter insulin sensitivity as measured by the minimal model or the euglycemic clamp technique. The effect of DHEA on peroxisomal beta-oxidation and de novo lipogenesis is not known. We conclude that a significant role for DHEA in the pharmacologic treatment of human obesity is unlikely.
authors.affiliation: Department of Internal Medicine, Medical College of Virginia, Richmond 23298, USA.
authors.forename: J N
authors.initials: JN
authors.lastname: Clore
mesh_terms: D000273:Adipose Tissue; D000818:Animals; D003687:Dehydroepiandrosterone / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D008660:Metabolism; D009765:Obesity / Q000188:drug therapy
chemical_list: D007328:Insulin; D003687:Dehydroepiandrosterone